Latest Recruitment News

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Merino & Co reported a robust quarter highlighted by the successful launch of its Merino possum range, strategic international hires, and a solid cash position of $3.02 million, positioning the company for sustained expansion.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

OpenLearning Limited reported a robust Q2 FY25 with 22% year-on-year SaaS ARR growth to $2.65 million, driven by significant multi-year contract wins and expanding global customer base. The company’s AI-powered LMS strategy is delivering larger deals and improved cash flow metrics.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

EDU Holdings has reported record first-half FY25 results, propelled by strong enrolment growth at its Ikon Institute, while its vocational arm ALG faces headwinds from tighter student visa policies.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Larvotto Resources has opened a $5 million Share Purchase Plan offering shares at a 13.5% discount to fund key development and exploration activities at its Hillgrove Project in NSW.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.